奥希替尼用于治疗EGFR突变型非小细胞肺癌的软脑膜疾病 - Suppr

Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.

作者信息

Hegde Aparna, Velcheti Vamsidhar

机构信息

Division of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.

Thoracic Medical Oncology, Perlmutter Cancer Center, New York University, New York, NY.

出版信息

J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.

DOI:10.1016/j.jtho.2020.08.016

PMID:33148407

Abstract

摘要

相似文献

Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.奥希替尼用于治疗EGFR突变型非小细胞肺癌的软脑膜疾病

J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.

Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。

J Thorac Oncol. 2021 Feb;16(2):e12-e14. doi: 10.1016/j.jtho.2020.10.016.

A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.对致编辑信的回应：奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。

J Thorac Oncol. 2021 Feb;16(2):e14. doi: 10.1016/j.jtho.2020.12.009.

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.奥希替尼治疗 EGFR 突变型非小细胞肺癌伴 EGFR 酪氨酸激酶抑制剂预处理性脑膜转移的疗效。

Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.

Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation.携带EGFR V843I种系突变的非小细胞肺癌患者对奥希替尼的反应

Lung Cancer. 2020 Dec;150:247-248. doi: 10.1016/j.lungcan.2020.09.019. Epub 2020 Sep 28.

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.阿法替尼帮助克服 NSCLC 伴脑膜转移患者奥希替尼后继发性耐药，该患者存在获得性 EGFR L718Q 突变：一例报告。

BMC Cancer. 2019 Jul 17;19(1):702. doi: 10.1186/s12885-019-5915-7.

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.奥希替尼改善了不论 T790M 突变状态如何的伴有脑膜转移的 EGFR 突变型 NSCLC 患者的总生存期。

J Thorac Oncol. 2020 Nov;15(11):1758-1766. doi: 10.1016/j.jtho.2020.06.018. Epub 2020 Jul 9.

Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.在中国非小细胞肺癌患者中鉴定出一种新型的对奥希替尼敏感的突变，即EGFR H773L。

J Thorac Oncol. 2020 Mar;15(3):e46-e48. doi: 10.1016/j.jtho.2019.11.018.

Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.在辅助治疗中，奥希替尼目前不应被视为EGFR突变型非小细胞肺癌的标准治疗方案。

J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.奥希替尼预防晚期 EGFR 突变型非小细胞肺癌脑膜转移的疗效：一项倾向评分匹配回顾性研究。

BMC Cancer. 2021 Jul 30;21(1):873. doi: 10.1186/s12885-021-08581-2.

引用本文的文献

Lazarus effect in a patient initially empirically treated with osimertinib for L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.奥希替尼治疗 L858R 突变型非小细胞肺癌伴脑膜疾病患者的拉扎勒斯效应：病例报告

Oncotarget. 2024 Jan 16;15:27-30. doi: 10.18632/oncotarget.28550.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献